MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

Published Date: 13 Sep 2024

Absolute improvement of almost 30%, doubling of duration of response with savolitinib

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast cancer patients' arms swell less after an effective lymph node transfer.

2.

Is Laughter Good for Blood Glucose Control?

3.

Congresswoman has cancer; the IRS is suing a controversial doctor; and caffeine and teenagers.

4.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

5.

On all CAR-T products, the FDA is calling for a new boxed warning.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot